中国生物制药TQB3205泛KRAS抑制剂获NMPA批准开展晚期恶性肿瘤临床试验

美股速递
Mar 11

中国生物制药宣布,其自主研发的TQB3205泛KRAS抑制剂已获得国家药品监督管理局(NMPA)批准,将针对晚期恶性肿瘤开展临床试验。该药物作为创新靶向治疗产品,有望为相关癌症患者提供新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10